■先前观察性研究的证据表明,单纯疱疹病毒(HSV)和水痘带状疱疹病毒(VZV)的感染会增加痴呆的风险。
■调查接受HSV治疗的老年人患痴呆症的风险是否低于其他人群。
■我们使用2013年至2022年的10%澳大利亚药品福利计划(PBS)数据库来确定横截面,HSV治疗暴露与抗痴呆药物分配之间的时间序列和纵向关联。参与者是60岁或以上的男性和女性。我们使用解剖治疗化学(ATC)代码来识别用于治疗HSV和痴呆症的药物。
■在2022年期间,559,561名60岁或以上的参与者中有6,868名(1.2%)被分配了抗痴呆药。在接受HSV治疗的个体中,接受抗痴呆药物治疗的比值比(OR)为0.73(99%CI=0.56-0.95)。2013-2022年期间给予HSV治疗的患者的多水平逻辑回归为0.87(99%CI=0.75-1.00)。相对于未分配HSV治疗的个体,2013年的分时间跨度系列与0.98的风险比(99%CI=0.89-1.07)相关。所有分析都根据年龄进行了调整,性别,以及分配治疗糖尿病的药物,高脂血症,高血压,缺血性心脏病.
■用于治疗HSV和VZV的抗病毒药物的分配是一致的,但不是决定性的,与抗痴呆药物的分配减少有关。这表明HSV和VZV感染的治疗可能有助于降低痴呆的风险。
UNASSIGNED: Evidence from previous observational studies suggest that infection by herpes simplex virus (HSV) and varicella zoster virus (VZV) increase the risk of dementia.
UNASSIGNED: To investigate if older adults exposed to HSV treatment have lower risk of dementia than the rest of the population.
UNASSIGNED: We used the 10% Australian Pharmaceutical Benefits Scheme (PBS) database from 2013 to 2022 to ascertain the cross-sectional, time-series and longitudinal association between exposure to HSV treatment and the dispensing of antidementia medicines. Participants were men and women aged 60 years or older. We used Anatomical Therapeutic Chemical (ATC) codes to identify medicines dispensed for the treatment of HSV and dementia.
UNASSIGNED: During the year 2022 6,868 (1.2%) of 559,561 of participants aged 60 years or over were dispensed antidementia agent. The odds ratio (OR) of being dispensed an antidementia agent among individuals dispensed treatment for HSV was 0.73 (99% CI = 0.56-0.95). Multilevel logistic regression for the 2013-2022 period for those dispensed HSV treatment was 0.87 (99% CI = 0.75-1.00). Split-time span series from 2013 was associated with hazard ratio of 0.98 (99% CI = 0.89-1.07) for individuals dispensed relative to those not dispensed HSV treatment. All analyses were adjusted for age, sex, and the dispensing of medicines for the treatment of diabetes, hyperlipidemia, hypertension, and ischemic heart disease.
UNASSIGNED: The dispensing of antiviral medicines for the treatment of HSV and VZV is consistently, but not conclusively, associated with decreased dispensing of antidementia medicines. This suggests that treatment of HSV and VZV infections may contribute to reduce the risk of dementia.